We pioneered the design of new biological function. Now we’re building a future where all cell therapies are effective and safe.
Today, only a tiny fraction of cancers can be cured. This is because cancer is a complex biological system, and our bodies have learned to make the wrong decisions as they fight. Our immune system evolved to beat back infections, not our own cells. Even the most advanced cancer treatments fail to address this.
Rather than one gene or one protein solutions that reuse existing biomolecules, we need to create better biology that can address the multiple mechanisms that stand in the way of curing tumors.
Proteins are the biological unit of function. Creating new ones will transform medicine.
Natural proteins represent only a sliver of the potential biological universe. By designing new protein functions, we can guide cells to recognize and eliminate cancer in the body. Our co-founders pioneered a new era in protein design, shifting from designing structures to new biological functions.
We know that cell therapies have the potential to cure cancer, but less than ~5% of cancer burden can be addressed with existing technology.
To cure solid tumors, multiple problems must be solved simultaneously: 1) the tumor suppresses our immune response, 2) the cell therapy does not persist, and 3) the cell therapy has limited potency, safety, and specificity.
By programming cells to make the right decisions inside patients, Outpace’s technologies stimulate productive immune responses in the tumor microenvironment (OUTSMART™), enable potent and persistent cell therapy activity (OUTLAST™), and maximize the potency (OUTSPACERS™), safety (OUTSAFE™) and specificity (CO-LOCKR™) of cell therapies across diverse cancer indications.
Protein design
Biostatistics
Next gen sequencing analysis
>100,000 hours of protein design experience
Cloning
Protein production
Lenti production
Automation
>10,000 constructs tested
Regulated promoters
Controlled cytokines
Autonomous protein regulators
Expansive parts library & stackable assets that solve barriers to efficacy & safety
Robust in-house translational models
Deep disease area expertise
IND engine for engineered
cell therapies
Protein design
Biostatistics
Next gen sequencing analysis
>100,000 hours of protein design experience
Cloning
Protein production
Lenti production
Automation
>10,000 constructs tested
Regulated Promoters
Controlled Cytokines
Autonomous Protein Regulators
Expansive parts library & stackable assets that solve barriers to efficacy & safety
IND engine for engineered
cell therapies
Robust in-house translational models and expertise